Does Siponimod Exert Direct Effects in the Central Nervous System?
The modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes in lymph nodes. Different sphingosine 1-phosphate receptor subtypes are expressed in the brain and spinal cord, and their...
Main Author: | Markus Kipp |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/8/1771 |
Similar Items
-
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
by: Newshan Behrangi, et al.
Published: (2019-01-01) -
Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
by: Kensuke Senzaki, et al.
Published: (2021-06-01) -
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01) -
New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01) -
New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01)